Insider Trading Alert - INSY, HF And NEWT Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 27, 2015, 82 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $945.00 to $3,999,999.00.

Highlighted Stocks Traded by Insiders:

Insys Therapeutics (INSY) - FREE Research Report

Fourteau Patrick, who is Director at Insys Therapeutics, sold 6,095 shares at $60.03 on May 27, 2015. Following this transaction, the Director owned 54,841 shares meaning that the stake was reduced by 10% with the 6,095-share transaction.

The shares most recently traded at $60.09, up $0.06, or 0.1% since the insider transaction. Historical insider transactions for Insys Therapeutics go as follows:

  • 4-Week # shares bought: 16,500
  • 4-Week # shares sold: 19,064
  • 12-Week # shares bought: 16,500
  • 12-Week # shares sold: 29,064
  • 24-Week # shares bought: 16,500
  • 24-Week # shares sold: 29,064

The average volume for Insys Therapeutics has been 471,500 shares per day over the past 30 days. Insys Therapeutics has a market cap of $2.1 billion and is part of the health care sector and drugs industry. Shares are up 45.28% year-to-date as of the close of trading on Wednesday.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company has a P/E ratio of 57.4. Currently, there are 4 analysts who rate Insys Therapeutics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on INSY - FREE

TheStreet Quant Ratings rates Insys Therapeutics as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, expanding profit margins and increase in net income. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Insys Therapeutics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

HFF (HF) - FREE Research Report

Sansosti Gerard T., who is Executive Managing Director at HFF, sold 1,950 shares at $39.09 on May 27, 2015. Following this transaction, the Executive Managing Director owned 69,637 shares meaning that the stake was reduced by 2.72% with the 1,950-share transaction.

The shares most recently traded at $40.00, up $0.91, or 2.27% since the insider transaction. Historical insider transactions for HFF go as follows:

  • 4-Week # shares sold: 51,740
  • 12-Week # shares sold: 160,410
  • 24-Week # shares sold: 198,410

The average volume for HFF has been 240,800 shares per day over the past 30 days. HFF has a market cap of $1.5 billion and is part of the financial sector and real estate industry. Shares are up 10.33% year-to-date as of the close of trading on Wednesday.

HFF, Inc. provides commercial real estate and capital market services to users and providers of capital in the commercial real estate industry in the United States. The company has a P/E ratio of 22.3. Currently, there are 2 analysts who rate HFF a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HF - FREE

TheStreet Quant Ratings rates HFF as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. Get the full HFF Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Newtek Business Services (NEWT) - FREE Research Report

Mulia Salvatore Francis, who is Director at Newtek Business Services, bought 2,000 shares at $17.66 on May 27, 2015. Following this transaction, the Director owned 44,785 shares meaning that the stake was boosted by 4.67% with the 2,000-share transaction.

The shares most recently traded at $14.39, down $3.27, or 22.72% since the insider transaction. Historical insider transactions for Newtek Business Services go as follows:

  • 4-Week # shares bought: 3,000
  • 4-Week # shares sold: 48
  • 12-Week # shares bought: 3,000
  • 12-Week # shares sold: 48
  • 24-Week # shares bought: 3,000
  • 24-Week # shares sold: 48

The average volume for Newtek Business Services has been 11,300 shares per day over the past 30 days. Newtek Business Services has a market cap of $107.8 million and is part of the services sector and diversified services industry. Shares are down 9.24% year-to-date as of the close of trading on Friday.

Newtek Business Services Corp., a business development company, provides financial and business services to the small-and medium-sized business market in the United States and internationally. The company has a P/E ratio of 15.9.

Exclusive Offer: Get the latest Stock Analysis on NEWT - FREE

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers